Comparison of transarterial n-BCA and Onyx embolization of brain arteriovenous malformations: A single-center 18-year retrospective analysis

다국어 초록 (Multilingual Abstract)

Objective: Brain arteriovenous malformations (AVM) are commonly treated with endovascular embolization. Due to the rapid evolution of endovascular technology and lack of consistent practice guidelines regarding AVM embolization, further study of AVM embolization outcomes is warranted.Methods: We conducted a retrospective review of AVMs embolized at a single center from 2002-2019. Patient demographics, AVM characteristics, intention of embolization, and angiographic and clinical outcome after embolization were recorded. We compared the embolization results of those treated with n-butyl cyanoacrylate (n-BCA) and Onyx.Results: Over an 18-year period at our institution, 30 (33%) of 92 AVMs were treated with embolization. n-BCA was used in 12 cases and Onyx in 18 cases. Eighty-seven pedicles were embolized over 47 embolization sessions. Fifty percent of AVMs treated with n-BCA underwent more than one embolization session compared to 22% when Onyx was used. The median total percent volume reduction in the n-BCA AVMs was 52% compared to 51% in Onyx AVMs. There were 2 periprocedural complications in the n-BCA cohort and none in the Onyx cohort.Conclusions: In this small retrospective series, Onyx and n-BCA achieved similar occlusion results, although n-BCA required more sessions and pedicles embolized to do so.

참고문헌 (Reference)

1 Pasqualin A, "The relevance of anatomic and hemodynamic factors to a classification of cerebral arteriovenous malformations" 28 (28): 370-379, 1991

2 Chapot R, "The pressure cooker technique for the treatment of brain AVMs" 41 (41): 87-91, 2014

3 Alexander MD, "Targeted embolization of aneurysms associated with brain arteriovenous malformations at high risk for surgical resection : A case-control study" 82 (82): 343-349, 2018

4 Foroni R, "Shape recovery and volume calculation from biplane angiography in the stereotactic radiosurgical treatment of arteriovenous malformations" 35 (35): 565-577, 1996

5 Imbesi SG, "Reproducibility analysis of a new objective method for measuring arteriovenous malformation nidus size at angiography" 23 (23): 412-415, 2002

6 Atkinson RP, "Reporting terminology for brain arteriovenous malformation clinical and radiographic features for use in clinical trials" 32 (32): 1430-1442, 2001

7 Jayaraman MV, "Reporting standards for angiographic evaluation and endovascular treatment of cerebral arteriovenous malformations" 4 (4): 325-330, 2012

8 Alaraj A, "Quantitative assessment of changes in cerebral arteriovenous malformation hemodynamics after embolization" 46 (46): 942-947, 2015

9 Sahlein DH, "Nidal embolization of brain arteriovenous malformations : rates of cure, partial embolization, and clinical outcome" 117 (117): 65-77, 2012

10 Elsenousi A, "Neurological outcomes and cure rates of embolization of brain arteriovenous malformations with n-butyl cyanoacrylate or Onyx : a meta-analysis" 8 (8): 265-272, 2016

11 Crowley RW, "Neurological morbidity and mortality associated with the endovascular treatment of cerebral arteriovenous malformations before and during the Onyx era" 122 (122): 1492-1497, 2015

12 Jayaraman MV, "Neurologic complications of arteriovenous malformation embolization using liquid embolic agents" 29 (29): 242-246, 2008

13 n-BCA Trail Investigators, "N-butyl cyanoacrylate embolization of cerebral arteriovenous malformations : results of a prospective, randomized, multi-center trial" 23 (23): 748-755, 2002

14 See AP, "Morbidity and mortality associated with sequential flow reduction embolization technique of cerebral arteriovenous malformations using n-butyl cyanoacrylate" 13 (13): 237-241, 2021

15 Mohr JP, "Medical management with interventional therapy versus medical management alone for unruptured brain arteriovenous malformations(ARUBA) : final follow-up of a multicentre, non-blinded, randomised controlled trial" 19 (19): 573-581, 2020

16 Weber W, "Endovascular treatment of intracranial arteriovenous malformations with onyx : technical aspects" 28 (28): 371-377, 2007

17 Pierot L, "Endovascular treatment of brain arteriovenous malformations using a liquid embolic agent : results of a prospective, multicentre study(BRAVO)" 23 (23): 2838-2845, 2013

18 Debrun GM, "Embolization of the nidus of brain arteriovenous malformations with n-butyl cyanoacrylate" 40 (40): 112-120, 1997

19 Frizzel RT, "Cure, morbidity, and mortality associated with embolization of brain arteriovenous malformations : a review of 1246 patients in 32 series over a 35-year period" 37 (37): 1031-1039, 1995

20 Haw CS, "Complications of embolization of arteriovenous malformations of the brain" 104 (104): 226-232, 2006

21 Vinuela F, "Combined endovascular embolization and surgery in the management of cerebral arteriovenous malformations : experience with 101 cases" 75 (75): 856-864, 1991

22 Heidenreich JO, "Bleeding complications after endovascular therapy of cerebral arteriovenous malformations" 27 (27): 313-316, 2006

23 Kashanian A, "Assessing the volume of large cerebral arteriovenous malformations : Can the ABC/2 formula reliably predict true volume?" 65 : 1-5, 2019

24 Solomon RA, "Arteriovenous malformations of the brain" 376 (376): 1859-1866, 2017

25 Roark C, "ABC/2 method does not accurately predict cerebral arteriovenous malformation volume" 82 (82): 220-225, 2018

26 Loh Y, "A prospective, multicenter, randomized trial of the Onyx liquid embolic system and N-butyl cyanoacrylate embolization of cerebral arteriovenous malformations. Clinical article" 113 (113): 733-741, 2010